- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01383772
Retinal Laser by Multi-spot Photocoagulator and Driving Eligibility
A Prospective Clinical Study of the Effects of Panretinal Photocoagulation Delivered With a Multi-spot Photocoagulator on Retinal Sensitivity and Driving Eligibility in Patients With Diabetic Retinopathy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite improvements in the management of diabetes, the incidence of severe diabetes -related eye disease remains high. Laser treatment (panretinal photocoagulation (PRP)) is the gold standard treatment for reducing the risk of visual loss. However, evidence suggests that PRP can be damaging on visual field function and thus jeopardize patients' eligibility to drive. In the UK, it is the patient's responsibility to inform the DVLA that they are receiving retinal laser.
With the use of a multi-spot Photocoagulator for application of PRP at Moorfields the investigators are in a unique position to assess the effects of laser applied with this new delivery system on visual fields in a detailed fashion. Thus providing more accurate advice on visual prognosis and visual field function and addressing the risk of losing the ability to drive.
All treatment-naive patients with severe diabetic retinopathy requiring bilateral retinal laser treatment will be identified. Following informed consent these patients will undergo baseline visual field testing which will be of a duration of approximately 30 minutes and complete a quality of life questionnaire. All patients will receive their laser treatment as part of standard clinical care via the multi-spot Photocoagulator which will require approximately four 20 minute sessions. At 6 months following the completion of treatment the patients will undergo repeat visual field testing as conducted at baseline and complete a quality of life questionnaire. The investigators hope to recruit 100 patients.
Analysis of visual fields will principally involve assessment of whether patients have met the UK driving standards on Estermann VF testing. A quantitative assessment of change in retinal sensitivity will be undertaken by comparing retinal sensitivity pre and post-PRP.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, EC1V2PD
- Moorfields Eye Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients of either sex aged 18 years or over.
- Diabetes mellitus (type 1 or type 2).
- Best corrected visual acuity (BCVA) > or equal 6/60 in both eyes.
- Requiring full bilateral PRP.
- No previous laser treatment.
- Subject cooperation sufficient for adequate visual field testing.
- Ability to return for regular study visits.
Exclusion Criteria:
- Co-existent ocular/systemic condition that may affect visual field.
- Visual acuity less than 6/60 that may affect accuracy of visual field test.
- Presence of vitreous haemorrhage.
- Intraocular surgery/other intervention anticipated in either eye during the duration of treatment and VF assessment.
- Previous PRP.
- Age below 18.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Visual fields
One arm study.
All patients will receive laser treatment following visual field testing.
|
All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment.
These fields will be repeated at 6 months following completion of laser treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Risk of failing visual field criteria to hold a driving licence.
Time Frame: visual fields at baseline and at 6 months.
|
All patients requiring bilateral PRP will be identified. These patients will undergo binocular and uniocular full-field static and kinetic visual field testing; All patients will receive their PRP via the multi-spot Photocoagulator using standardised parameters for treatment. At 6 months following the completion of PRP the patients will undergo repeat visual field testing as conducted at baseline. Analysis of visual fields will principally involve qualitative assessment of whether patients have met the UK driving standards on Estermann VF testing. |
visual fields at baseline and at 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual field assessment prior to planned pan retinal photocoagulation
Time Frame: at baseline
|
Evaluation of full-field retinal sensitivity with visual field tests in patients with severe pre-proliferative or proliferative DR prior to planned PRP. A quantitative assessment of retinal sensitivity using the mean global retinal sensitivity and measuring the entire hill-of-vision. This will also be addressed at 6 months following PRP to compare to pre- treatment values. |
at baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Michel Michaelides, FRCOphth, Moorfields Eye Hospital NHS Foundation Trust
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MICM1005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Proliferative Diabetic Retinopathy
-
Bojie HuCompletedProliferative Diabetic RetinopathyChina
-
Ocular Therapeutix, Inc.RecruitingNon-Proliferative Diabetic RetinopathyUnited States
-
AJU Pharm Co., Ltd.CompletedNon-Proliferative Diabetic RetinopathySouth Korea
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingNon-proliferative Diabetic Retinopathy (NPDR)
-
Ahalia Foundation Eye HospitalCompletedProliferative Diabetic Retinopathy | Retinal Detachment | Proliferative Vitreo-RetinopathyIndia
-
Eye & ENT Hospital of Fudan UniversityNot yet recruitingProliferative Diabetic Retinopathy | Photocoagulation Burn to RetinaChina
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoTerminatedProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoTerminatedProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Valo Health, Inc.Active, not recruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
Clinical Trials on Pan retinal Photocoagulation
-
Lawson Health Research InstituteCompleted
-
United Christian HospitalThe University of Hong KongCompletedDiabetic Retinopathy | Lasers | Treatment Outcome
-
Afyon Kocatepe University HospitalCompletedRetinal Degeneration | Diabetic Retinopathy | Macula Abnormality | Laser Burn of Retina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Queen's University, BelfastRecruitingDiabetic RetinopathyChina
-
University of MalayaUnknownProliferative Diabetic RetinopathyMalaysia
-
Charles C Wykoff, PhD, MDGenentech, Inc.CompletedCentral Retinal, Hemi Retinal & Brach Retinal Vein OcclusionsUnited States
-
David M. Brown, M.D.Genentech, Inc.CompletedDiabetic Macular EdemaUnited States
-
Wills EyeMid Atlantic RetinaCompletedProliferative Diabetic Retinopathy - High RiskUnited States
-
Cairo UniversityCompletedDiabetic Retinopathy | Proliferative Diabetic Retinopathy | Vascular Endothelial Growth Factor OverexpressionEgypt
-
Odense University HospitalMoorfields Eye Hospital NHS Foundation Trust; University of Southern Denmark; Yamagata University and other collaboratorsCompletedProliferative Diabetic RetinopathyDenmark